I did a comparision of the two trials in a different thread which ill copy below:
Lets do a comparison of Ruxolitnib vs Remestemcel-L trials: Trial:
Single arm open label 49 patients
Single arm open label 54 patients (Study 001)
Day 28 ORR:
40.7%-44.4% on grade 3-4 (grade c-d)
61%-67% on grade 3-4 (grade c-d)
Day 180 Survival:
51% (n=25)
69% (n=37)
Safety:
Multiple safety concerns/side effects including infections, sepsis, uti's, thrombosis and animia (adverse events lead to 31% of patients discontinuing treatment)
No safety concerns identified with a safety profile similar to placebo (adverse events lead to 15% of patients discontinuing treatment)
FDA Decision
Approved
ODAC voted 9-1 in favour of efficacy however FDA issued a CRL recommending a further trial to establish efficacy and to provide more scientific rationale to demonstrate potency relationships
Ruxolitnib has had a previous trial for the treatment of myelofibrosis. The trial results clearly show that from the available data, Remestemcel-L is a superior treatment with a much better safety profile.
Could msb argue that if the COVID-19 trial is successful this would provide sufficient evidence of relevant efficacy and safety similar to Ruxolitnib extension from myelofibrosis to GvHD based on the 1 single arm trial above?
MSB Price at posting:
$3.44 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)